Fasken

Cycle Momentum is a Montreal-based accelerator established in 2014 that focuses on supporting cleantech startups. It is dedicated to working with entrepreneurs who develop and commercialize innovative clean technologies, aiming to cultivate globally competitive companies. The accelerator provides a tailored program that includes training workshops, networking opportunities, and access to experienced mentors. Additionally, Cycle Momentum connects these startups with investors to enhance their growth potential. By concentrating on seed-stage, early-stage, and later-stage companies, particularly in B2B, commercial transportation, energy, and cleantech sectors, Cycle Momentum plays a crucial role in fostering the development of promising Canadian ventures in the clean technology arena.

Pro Bono Ontario (PBO) bridges the gap between lawyers who want to donate their services and low-income Ontarians who cannot afford a lawyer or qualify for legal aid.

Asmacure Ltée is a clinical-stage biopharmaceutical company based in Quebec City, Canada, focused on developing proprietary compounds that target cholinergic receptors to address inflammation in pulmonary airway diseases. Established in 2002 by Dr. Yvon Cormier and Dr. Evelyne Israel-Assayag, the company’s lead product, ASM-024, is designed for the treatment of moderate asthma and chronic obstructive pulmonary disease (COPD). This compound features a novel multi-functional mechanism that encompasses anti-inflammation, bronchoprotection, and smooth muscle relaxation. ASM-024 has undergone clinical evaluation, demonstrating significant effects on lung function in phase 2 trials. The formulation is being developed as a dry powder for inhalation, which is expected to enhance lung deposition and optimize dosing for patients. As of 2015, Asmacure operates as a subsidiary of Odan Laboratories Ltd.